1.国家自然科学基金，PEAR1基因多态性在抗血小板疗效个体差异中的作用及其机制研究

2.“十三五”国家重点研发计划项目分课题，中国冠心病患者血栓和出血风险评分系统的研究

3.国家自然科学基金, ABCB1基因在P2Y12受体拮抗剂类抗血小板药物引发消化道出血中的作用及其分子机制研究

4. 国家心血管疾病临床医学研究中心PI课题，基于新型生物标志物的急性冠脉综合征风险预测模型的开发与验证研究

5. 中国医学科学院临床与转化医学研究基金，冠心病多支复杂病变的危险分层及优化干预策略

6.“十二五”国家支撑计划分课题“中国冠心病病人细胞色素P450(CYP)家族及血小板ADP受体(P2Y12)基因多态性与血栓事件的相关性研究” 

7.国家重点基础研究发展计划(973计划)分课题“镁合金血管支架的生物适配机制”

8.国家自然科学基金“抗血小板聚集药物氯吡格雷引发出血的分子机制研究”

9.北京市科技计划“全降解镁合金药物涂层支架的关键技术研究”

1.        Zhang C, Jiang L, Xu L, et al. ImplicationsofN-terminal pro-B-type natriuretic peptide in patients withthree-vesseldisease. Eur Heart J. 2019;40(41):3397-3405. (IF:22.67)

2.        Xiao-Fang Tang, Jin-Qing Yuan, et al. Biodegradablepolymer drug-eluting stents versus second-generation drug-eluting stents inpatients with and without diabetes mellitus: a single-center study.[J].Cardiovasc Diabetol, 2018, 17(1): 114. (IF：7.33)

3.        Yao Y, Tang XF, He C, et al. Effect of PEAR1Genetic Variants on 1-Year Outcomes in Chinese Patients with Acute MyocardialInfarction After Percutaneous Coronary Intervention. J Atheroscler Thromb. 2018;25(5):454-459. (IF:3.87)

4.         Ying Song, Jin-Qing Yuan et al., Impact ofresidual SYNTAX score on clinical outcomes after incompleterevascularization percutaneous coronary intervention: a large single-centrestudy, Eurointerv.,2017, 13: 1185-1193. (IF:3.99)

5.        Song Y, Tang XF, Yao Y, et al. Association ofα2A-Adrenergic Receptor Genetic Variants with Platelet Reactivity in ChinesePatients on Dual Antiplatelet Therapy Undergoing Percutaneous CoronaryIntervention. Biomed Environ Sci. 2017;30(12):898-906. (IF:2.65)

6.        Zhang JH, Wang J, Tang XF, et al. Effect ofplatelet receptor gene polymorphisms on outcomes in ST-elevation myocardialinfarction patients after percutaneous coronary intervention. Platelets. 2016;27(1):75-79. (IF:3.37)

7.        Yao Y, Tang XF, Zhang JH, et al. Association ofPEAR1 genetic variants with platelet reactivity in response to dualantiplatelet therapy with aspirin and clopidogrel in the Chinese patientpopulation after percutaneous coronary intervention. Thromb Res. 2016;141:28-34. (IF:2.86)

8.        Tang XF, Han YL, Zhang JH, et al. CYP2C19genotyping combined with on-clopidogrel platelet reactivity in predicting majoradverse cardiovascular events in Chinese patients with percutaneous coronaryintervention. Thromb Res. 2016;147:108-114. (IF:2.86)

9.        Yao Y, Zhang JH, Tang XF, et al. Head to HeadComparison of Two Point-of-care Platelet Function Tests Used for Assessment ofOn-clopidogrel Platelet Reactivity in Chinese Acute Myocardial InfarctionPatients Undergoing Percutaneous Coronary Intervention. Chin Med J (Engl). 2016;129(19):2269-2274. (IF:1.58)

10.     Tang XF, Han YL, Zhang JH, et al. Comparing of light transmittanceaggregometry and modified thrombelastograph in predicting clinical outcomes inChinese patients undergoing coronary stenting with clopidogrel. Chin Med J (Engl). 2015;128(6):774-779. (IF:1.58)

11.     Zhang JH, TangXF, Zhang Y, et al. Relationship between ABCB1 polymorphisms,thromboelastography and risk of bleeding events in clopidogrel-treated patientswith ST-elevation myocardial infarction. Thromb Res. 2014;134(5):970-975. (IF:2.86)

12.     Tang XF, Zhang JH, Wang J, et al. Effects of coexisting polymorphisms ofCYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome inpatients with acute coronary syndromes undergoing stent-based coronaryintervention. Chin Med J (Engl). 2013;126(6):1069-1075. (IF:1.58)

13.     Tang XF, WangJ, Zhang JH, et al. Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T andPON1 Q192R alleles on the pharmacodynamics and adverse clinical events ofclopidogrel in Chinese people after percutaneous coronary intervention. EurJ Clin Pharmacol. 2013;69(5):1103-1112.(IF:2.64)